Skip to Content

Showing 1-1 of 1

Sorted By:

  • ENGAGE AF

    This study is to demonstrate the safety and efficacy profile, in two different dose regimens of Edoxaban (DU-176b), (an investigational new drug being tested for the prevention of stroke/systemic embolic events (SEE)), in individuals with atrial fibrillation.

Showing trial 1 of 1

Also in this Section